參考文獻 |
1.Becker RA, Chambers JM and Wilks AR. The New S Language: a programming environment for data analysis and graphics. Chapman & Hall, June 1988.
2.Dubin J, Muller HG, Wang JL. Event history graphs of censored survival data. Statistics in Medicine 2001;20:2951-2964.
3.Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315(7117):1194-9
4.Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis. 2004; 190(5):879-85.
5.Gulick RM, Meibohm A, Havlir D, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine and lamivudine. AIDS 2003; 17:2345-9.
6.Henderson , R., Diggle, P. & Dobson, A. (2000). Joint modelling of longitudinal measurements and event time data. Biostatistics 4, 465–480.
7.Hsieh F, Tseng YK, Wang JL. Joint Modeling of Survival Time and Longitudinal Data: Likelihood Approach Revisit. Biometrics, 62, 1037-1043, 2006.
8.Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003; 163:2187-95.
9.Lucas CM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-87.
10.Prentice RL. Covariate measurement errors and parameter estimation in a failure time regression model. Biometrika, 69, 331-342, 1982.
11.Pawitan Y and Self S. Modeling disease marker process in AIDS. Journal of the American Statistical Association, Vol. 88, No. 423. (Sep., 1993), 719-726
12.Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60.
13.Tsiatis AA, DeGruttola V & Wulfsohn MS (1995). Modeling the relationship of survival to longitudinal data measured with error. Applications to survival and CD4 counts in patients with AIDS. Journal of the American Statistical Association 90, 27-37.
14.Tsiatis AA & Davidian M (2001). A semiparametric estimator for the proportional hazards model with longitudinal covariates measured with error. Biometrika 88, 447–458.
15.Tsiatis AA and Davidian M. Joint modeling of longitudinal and time-to-event data: an overview. Statistica Sinica 2004; 14:809-34.
16.Tseng YK, Hsieh F and Wang JL. Joint modeling of accelerated failure time and longitudinal data. Biometrika 2005; 92:587-603.
17.Wulfsohn MS, Tsiatis AA. A Joint Model for Survival and Longitudinal Data Measured with Error. Biometrics, Vol. 53, No. 1. (Mar., 1997), 330-339.
18.Wang Y & Taylor JMG (2001). Jointly modeling longitudinal and event time data with application to acquired immunodeficiency syndrome. J. Am. Statist. Assoc. 96, 895–905.
19.Yu M, Law NJ, Taylor JMG & Sandler HM (2004). Joint longitudinal-survival-cure models and their application to prostate cancer. Statist. Sinica 14, 835–62.
20.Zeng D, Cai J. Asymptotic results for maximum likelihood estimators in joint analysis of repeated measurements and survival time. The Annals of Statistics 2005; 33(5):2132-63. |